These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 4374702)
21. The development and specific suppression of concomitant immunity in two syngeneic tumour-host systems. Chandradasa KD Int J Cancer; 1973 May; 11(3):648-62. PubMed ID: 4598551 [No Abstract] [Full Text] [Related]
22. Cellular and humoral immunity after allogeneic transplantation in the rat. 3. The effect of passive antibody on cellular and humoral immunity after allogeneic renal transplantation. Biesecker JL; Fitch FW; Rowley DA; Stuart FP Transplantation; 1973 Nov; 16(5):432-40. PubMed ID: 4584953 [No Abstract] [Full Text] [Related]
24. Normal tissue antigens of tumor cells. Milas L; Suit HD Tex Rep Biol Med; 1969; 27(2):467-9. PubMed ID: 4900374 [No Abstract] [Full Text] [Related]
25. Cellular and humoral immunity after allogeneic transplantation in the rat. IV. The effect of heterologous antilymphocyte serum on cellular and humoral immunity after allogeneic renal transplantation. Biesecker JL; Fitch FW; Rowley DA; Stuart FP Transplantation; 1973 Nov; 16(5):441-50. PubMed ID: 4584954 [No Abstract] [Full Text] [Related]
26. Immunogenic properties of a soluble tumor-specific transplantation antigen induced by Simian virus 40. Drapkin MS; Appella E; Law LW J Natl Cancer Inst; 1974 Jan; 52(1):259-64. PubMed ID: 4129833 [No Abstract] [Full Text] [Related]
27. Effects of BCG on various facets of the immune response against polyoma tumors in rats. Bansal SC; Sjögren HO Int J Cancer; 1973 Jan; 11(1):162-71. PubMed ID: 4364321 [No Abstract] [Full Text] [Related]
28. Cellular and humoral immunity after allogeneic transplantation in the rat. II. Comparison of a 51Cr release assay and modified microcytotoxicity assay for detection of cellular immunity and blocking serum factors. Biesecker JL; Fitch FW; Rowley DA; Scollard D; Stuart FP Transplantation; 1973 Nov; 16(5):421-31. PubMed ID: 4584952 [No Abstract] [Full Text] [Related]
29. Thymus-derived lymphocytes as effectors of cell-mediated immunity to syngeneic and allogeneic transplants in the rat. Tucker DF; Dennert G; Lennox ES J Immunol; 1974 Oct; 113(4):1302-12. PubMed ID: 4547337 [No Abstract] [Full Text] [Related]
30. In vivo activity of in vitro immunized lymphocytes. I. Tumor allograft rejection mediated by in vitro activated mouse thymocytes. Rouse BT; Wagner H; Harris AW J Immunol; 1972 May; 108(5):1353-61. PubMed ID: 4623947 [No Abstract] [Full Text] [Related]
31. Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes. Milas L; Hunter N; Mason K; Withers HR Cancer Res; 1974 Jan; 34(1):61-71. PubMed ID: 4809463 [No Abstract] [Full Text] [Related]
32. Cytotoxic isoantibodies and immunologic enhancement in mice. Cruse JM Proc Soc Exp Biol Med; 1966 Mar; 121(3):833-8. PubMed ID: 5935596 [No Abstract] [Full Text] [Related]
33. Immunospecific regression of methylcholanthrene fibrosarcoma using neuraminidase. 3. Synergistic effect of BCG and neuraminidase treated tumor cells. Simmons RL; Rios A Ann Surg; 1972 Aug; 176(2):188-94. PubMed ID: 4562008 [No Abstract] [Full Text] [Related]
34. Tumor immunity in vivo: evidence that immune destruction of tumor leaves "bystander" cells intact. Weissman IL J Natl Cancer Inst; 1973 Aug; 51(2):443-8. PubMed ID: 4765368 [No Abstract] [Full Text] [Related]
35. Effect of antibody to theta antigen on cell-mediated immunity induced in syngeneic mice by murine sarcoma virus. Herberman RB; Nunn ME; Lavrin DH; Asofsky R J Natl Cancer Inst; 1973 Nov; 51(5):1509-12. PubMed ID: 4543478 [No Abstract] [Full Text] [Related]
36. Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase. Simmons RL; Rios A; Lundgren G; Ray PK; McKhann CF; Haywood GR Surgery; 1971 Jul; 70(1):38-46. PubMed ID: 5092115 [No Abstract] [Full Text] [Related]
37. Increased growth of tumor isotransplants after immunosuppression of the recipient mice by methotrexate or 5-fluoro-2'-deoxyuridine. Reiner J; Southam CM J Natl Cancer Inst; 1967 May; 38(5):753-9. PubMed ID: 4225921 [No Abstract] [Full Text] [Related]
38. [Persistance of cytotoxic activity against a syngeneic tumor after removal of the tumor]. Lafontaine N; Firket H C R Acad Hebd Seances Acad Sci D; 1973 Oct; 277(13):1261-3. PubMed ID: 4205925 [No Abstract] [Full Text] [Related]
39. Discussion paper: in vitro augmentation of tumor immunity in a murine methylcholanthrene sarcoma system. Yarlott MA; McKhann CF Ann N Y Acad Sci; 1976; 277(00):533-40. PubMed ID: 187102 [No Abstract] [Full Text] [Related]
40. Immune reactions of the syngeneic host after the intradermal injection of tumor cells and microsomes. Bertschmann M; Lüscher EF Adv Exp Med Biol; 1973; 29(0):513-8. PubMed ID: 4212066 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]